Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ETHINYL ESTRADIOL & NORETHINDRONE

All products: general benefit

Other products in the same Health Canada class (G03A, G03AB) — coverage varies; not interchangeable

  • Desogestrel + ethinyl estradiol (Marvelon 21): general benefit
  • Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, Not a benefit
  • Ethinyl estradiol + norgestimate (Tri-Cyclen): general benefit, Not a benefit
  • Drospirenone (Slynd): general benefit
  • Drospirenone + ethinyl estradiol (Yasmin 21): general benefit
  • Ethinyl estradiol + norethindrone (Minestrin 1/20): general benefit

3 more in the class list below

Synphasic · DIN 02187116 · 3 Phase · tablets, 28-pack

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Synphasic · DIN 02187116 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2006-07-20 · brand SYNPHASIC 28 TABLETS · ATC G03AB04 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE 0.5 MG, ETHINYL ESTRADIOL 0.035 MG, NORETHINDRONE 1.0 MG, ETHINYL ESTRADIOL 0.035 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Synphasic: Formulary list price $13.6400/unit (unit not stated in source; not the patient's cost)

Ministry pays: $13.6400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42890 · Verify on the e-Formulary ↗ (DIN 02187116)

Source record
DIN 02187116: Synphasic Raw flags: sec3=Y Item: 683200060; group id 798; item number 1951; lccId None; manufacturer id PFI Source form: Tab-28 Pk; strength: 3 Phase Recorded listing: General benefit Source prices (unrounded): $13.6400; ministry $13.6400 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02187116 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42890
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187116
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:32 Progestogens and Oral Contraceptives) and how they are covered

Matched class: 68:32 Progestogens and Oral Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE, DROSPIRENONE & ETHINYL ESTRADIOL, ETHINYL ESTRADIOL & NORETHINDRONE ACETATE, LEVONORGESTREL Some products covered without a code (check the product listing): ETHINYL ESTRADIOL & LEVONORGESTREL, MEDROXYPROGESTERONE ACETATE, NORETHINDRONE, NORGESTIMATE & ETHINYL ESTRADIOL 68:32 Progestogens and Oral Contraceptives

DESOGESTREL & ETHINYL ESTRADIOL

· 12 products · General benefit · strengths: 0.15mg & 0.03mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tabs-21 Pk, Tabs-28 Pk

ETHINYL ESTRADIOL & LEVONORGESTREL

· 20 products · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 20mcg & 100mcg, 0.03mg & 0.15mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tab-91 Pk

NORGESTIMATE & ETHINYL ESTRADIOL

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 3 Phase · Tab-21 Pk, Tab-28 Pk

DROSPIRENONE

· 1 products · General benefit · strengths: 4mg · Tab-28 Tab Pk

DROSPIRENONE & ETHINYL ESTRADIOL

· 9 products · General benefit · strengths: 3.0mg & 0.03mg, 3.0mg & 0.02mg · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & NORETHINDRONE ACETATE

· 4 products · General benefit · strengths: 0.02mg & 1mg, 0.03mg & 1.5mg · Tab-21 Pk, Tab-28 Pk

LEVONORGESTREL

· 4 products · General benefit · strengths: 1.5mg · Tab-1 Tab Pk

MEDROXYPROGESTERONE ACETATE

· 10 products · Temporary benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (4), Listed, not a benefit (1) · strengths: 150mg/mL, 2.5mg, 5mg, 10mg, 100mg · Inj Sol-1mL Pref Syr, Tab

NORETHINDRONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 0.35mg · Tab-28 Pk

DIENOGEST

· 5 products · Limited Use, codes 432 · strengths: 2mg · Tab

CYPROTERONE ACETATE & ETHINYL ESTRADIOL

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg & 0.035mg · Tab-21 Pk

PROGESTERONE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:32
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: pregnancy
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. NORETHINDRONE ACETATE/ETHINYL ESTRADIOL & ETHINYL ESTRADIOL · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS LOLO® (ethinyl estradiol / norethindrone acetate and ethinyl estradiol) is indicated for: • the prevention of pregnancy. PM: https://pdf.hres.ca/dpd_pm/00077458.PDF; date DEC 12, 2013; DIN 02417456; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications BREVICON 0.5/35 and BREVICON 1/35 (norethindrone and ethinyl estradiol) are indicated for: • the prevention of pregnancy. 1.1. Pediatrics The safety and efficacy of BREVICON has been established in women of reproductive age. Use of these products before menarche is not indicated. 1.2. Geriatrics BREVICON is not indicated for use in postmenopausal women. https://pdf.hres.ca/dpd_pm/00081309.PDF PM date: 2025-08-07 Source product: BREVICON 0.5/35 TABLETS (21-DAY PACK); DIN 02187086; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Synphasic · DIN 02187116 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187116

Check this DIN again